- Home
- SPRY vs RCUS Comparison
SPRY vs RCUS Comparison
Compare SPRY & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- RCUS
- Stock Information
- Founded
- SPRY 2015
- RCUS 2015
- Country
- SPRY United States
- RCUS United States
- Employees
- SPRY 24
- RCUS N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- SPRY Health Care
- RCUS Health Care
- Exchange
- SPRY Nasdaq
- RCUS Nasdaq
- Market Cap
- SPRY 1.4B
- RCUS 1.4B
- IPO Year
- SPRY N/A
- RCUS 2018
- Fundamental
- Price
- SPRY $14.01
- RCUS $15.72
- Analyst Decision
- SPRY Strong Buy
- RCUS Buy
- Analyst Count
- SPRY 4
- RCUS 12
- Target Price
- SPRY $24.00
- RCUS $34.50
- AVG Volume (30 Days)
- SPRY 1.3M
- RCUS 932.9K
- Earning Date
- SPRY 11-13-2024
- RCUS 11-06-2024
- Dividend Yield
- SPRY N/A
- RCUS N/A
- EPS Growth
- SPRY N/A
- RCUS N/A
- EPS
- SPRY N/A
- RCUS N/A
- Revenue
- SPRY $2,568,000.00
- RCUS $263,000,000.00
- Revenue This Year
- SPRY $21,686.67
- RCUS $112.97
- Revenue Next Year
- SPRY $956.61
- RCUS N/A
- P/E Ratio
- SPRY N/A
- RCUS N/A
- Revenue Growth
- SPRY 8460.00
- RCUS 119.17
- 52 Week Low
- SPRY $4.53
- RCUS $13.50
- 52 Week High
- SPRY $18.51
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- SPRY 41.90
- RCUS 43.78
- Support Level
- SPRY $13.80
- RCUS $15.03
- Resistance Level
- SPRY $18.51
- RCUS $18.98
- Average True Range (ATR)
- SPRY 1.23
- RCUS 1.02
- MACD
- SPRY -0.24
- RCUS -0.04
- Stochastic Oscillator
- SPRY 12.62
- RCUS 20.07
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.